Digoxin has long been used in patients with heart failure (HF) and then atrial fibrillation (AF), given its ability to inhibit the Na + /K + ATPase (NKA), decelerate cardiomyocyte repolarisation, and enhance contractility [1, 2]. The gene discussed is TAC1; the disease is atrial fibrillation.